Immunotherapy biotech Tobira Therapeutics files for a $69 million IPO to treat NASH and HIV

By
A A A

Tobira Therapeutics, a biotech developing an immunotherapy treatment for liver disease ( NASH ) and HIV, filed on Monday with the SEC to raise up to $69 million in an initial public offering. The San Francisco, CA-based company, which was founded in 2006, plans to list on the NASDAQ under the symbol TBRA. BMO Capital Markets, JMP Securities and Oppenheimer are the joint bookrunners on the deal. No pricing terms were disclosed.




The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: News Headlines , IPOs

Referenced Stocks: NASH

Renaissance Capital

Renaissance Capital

More from Renaissance Capital:

Related Videos

Stocks

Referenced

100%

Most Active by Volume

33,110,376
  • $113.99 ▲ 1.77%
25,034,179
    $17.98 unch
24,486,872
  • $7.41 ▲ 2.07%
20,864,535
  • $7.39 ▼ 2.76%
18,600,501
  • $8.30 ▼ 0.36%
17,530,211
  • $8.14 ▲ 3.17%
17,299,208
  • $93.79 ▲ 2.74%
14,669,760
  • $25.78 ▼ 0.19%
As of 12/26/2014, 04:15 PM


Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com